OCM
JANX icon

Ovata Capital Management’s Janux Therapeutics JANX Stock Holding History

Ovata Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$454K – 36
2024
Q3 		$454K Sell
10,000
-10,000
-50% -$435K 0.19% 27
2024
Q2 		$838K Sell
20,000
-20,000
-50% -$939K 0.46% 28
2024
Q1 		$1.51M Buy
+40,000
New +$871K 0.78% 24

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Ovata Capital Management's JANX Position: Q4 2024 in Review

Ovata Capital Management sold out of Janux Therapeutics (JANX) in Q4 2024, closing a stake of 10,000 shares — an estimated $454K sold.

Ovata Capital Management first reported a position in JANX in Q1 2024 and held it in 3 quarters. The position peaked at $1.51M in Q1 2024. 216 funds tracked by Wall St. Rank hold JANX as of Q4 2024.

  • Ovata Capital Management reported no remaining Janux Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Ovata Capital Management sold 10,000 Janux Therapeutics shares in Q4 2024, an estimated $454K.
  • Ovata Capital Management first reported a position in Janux Therapeutics in Q1 2024 and held it in 3 quarters.
  • Ovata Capital Management's Janux Therapeutics position peaked at $1.51M in Q1 2024.
  • 216 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2024.

Based on Ovata Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.